Department of Neurological Surgery, University of Miami, Jackson Memorial Hospital, Miami, FL, USA.
Department of Neurological Surgery, University of Miami Miller School of Medicine, 1095 NW 14th Terrace, 33136, Miami, FL, USA.
J Neurooncol. 2023 Dec;165(3):439-447. doi: 10.1007/s11060-023-04538-6. Epub 2023 Dec 19.
Surgical resection of glioblastoma (GBM) remains a cornerstone in the current treatment paradigm. The postoperative evolution of hydrocephalus necessitating ventriculoperitoneal shunting (VPS) continues to be defined. Correspondingly the objective of this study was to aggregate pertinent metadata to better define the clinical course of VPS for hydrocephalus following glioblastoma surgery in light of contemporary management.
Searches of multiple electronic databases from inception to November 2023 were conducted following PRISMA guidelines. Articles were screened against pre-specified criteria. Outcomes were pooled by random-effects meta-analyses where possible.
A total of 12 cohort studies satisfied all selection criteria, describing a total of 6,098 glioblastoma patients after surgery with a total of 261 (4%) of patients requiring postoperative VPS for hydrocephalus. Meta-analysis demonstrated the estimated pooled rate of symptomatic improvement following VPS was 78% (95% CI 66-88), and the estimated pooled rate of VPS revision was 24% (95% CI 16-33). Pooled time from index glioblastoma surgery to VPS surgery was 4.1 months (95% CI 2.8-5.3), and pooled survival time for index VPS surgery was 7.3 months (95% CI 5.4-9.4). Certainty of these outcomes were limited by the heterogenous and palliative nature of postoperative glioblastoma management.
Of the limited proportion of glioblastoma patients requiring VPS surgery for hydrocephalus after index surgery, 78% patients are expected to show symptom improvement, and 24% can expect to undergo revision surgery. An individualized approach to each patient is required to optimize both index glioblastoma and VPS surgeries to account for anatomy and goals of care given the poor prognosis of this tumor overall.
手术切除胶质母细胞瘤(GBM)仍然是当前治疗模式的基石。需要脑室腹腔分流术(VPS)来治疗术后脑积水的演变仍在定义中。相应地,本研究的目的是聚合相关元数据,以便根据当代管理更好地定义胶质母细胞瘤手术后脑积水的 VPS 临床过程。
根据 PRISMA 指南,从开始到 2023 年 11 月对多个电子数据库进行了搜索。根据预先规定的标准筛选文章。如果可能,通过随机效应荟萃分析汇总结果。
共有 12 项队列研究符合所有选择标准,共描述了 6098 例手术后胶质母细胞瘤患者,其中 261 例(4%)患者需要术后 VPS 治疗脑积水。荟萃分析表明,VPS 后症状改善的估计 pooled 率为 78%(95%CI 66-88),VPS 修订的估计 pooled 率为 24%(95%CI 16-33)。从指数胶质母细胞瘤手术到 VPS 手术的 pooled 时间为 4.1 个月(95%CI 2.8-5.3),指数 VPS 手术的 pooled 生存时间为 7.3 个月(95%CI 5.4-9.4)。这些结果的确定性受到术后胶质母细胞瘤管理的异质性和姑息性的限制。
在需要指数手术后 VPS 手术治疗脑积水的有限比例的胶质母细胞瘤患者中,预计 78%的患者将出现症状改善,24%的患者可能需要接受修订手术。需要对每个患者进行个体化治疗,以优化指数胶质母细胞瘤和 VPS 手术,以考虑到总体上这种肿瘤的预后较差,以及解剖结构和治疗目标。